retatrutide trial data study sees significant weight loss in obesity drug study Retatrutide Starting Dose: What Clinical

Childhood Obesity , 20(3), 208-218

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used to manage type 2 diabetes in the UK

Retatrutide can unmask or worsen pre-existing conditions including thyroid dysfunction, iron deficiency anemia, vitamin D deficiency, and adrenal insufficiency

Final thoughts A natural alternative to GLP1 is not a single pill or food but a coherent, clinicianinformed program of fiber, protein, movement and selective supplements

The Rise of Oral GLP-1 Therapies After injectable GLP-1 therapies set new efficacy standards, industry focus is shifting toward oral delivery